Kaplan-Meier curves for progression-free survival (PFS). Graph A displays PFS by BMI category(Normal, Underweight, Overweight, Obesity). Graph B shows PFS by BMI change group(Decreased <2%, Decreased ≥2%). Graph C represents PFS by PNI category(Normal PNI, Low PNI).

Pretreatment BMI loss and low PNI predicted shorter progression-free survival in immunotherapy-treated #HNSCC, while baseline BMI category was not associated with outcome. ja.ma/4sMn6vf

#TenascinC orchestrates #radiotherapy -induced head and neck tumor regression #HNSCC by T. Loustau, G. Orend & colleagues @unistra.fr @inserm.fr

🗞️ doi.org/10.1038/s44321-026-00406-8

This #STTT study reveals that the Spi-1 #ProtoOncogene regulates mRNA hypertranscription to drive malignant progression in #HNSCC, offering a novel #TherapeuticTarget for hypertranscriptional HNSCC subtypes.

#OpenAccess: doi.org/10.1038/s413...

The combo of tislelizumab and chemotherapy produced sustained and clinically meaningful survival benefits with manageable toxicity among patients with recurrent or metastatic #nasopharyngealCancer. From @jamaoncology.com

Read more here: ➡️ https://bit.ly/4rTgs5h

#HeadandNeckCancer #HNSCC #MedOnc

Keytruda cleared for NHS use in early head and neck cancer MSD's Keytruda is poised to end a 20-year drought in new advances in NHS treatment for early-stage head and neck cancer

#Keytruda #pembrolizumab #immunotherapy #headandneckcancer #PharmaNews #MSD #NICE #reimbursement #NICEfinaldraftguidance #NHSEngland #headandnecksquamouscellcarcinoma #HNSCC #LAHNSCC #PDL1biomarker #PD1inhibitor #KEYNOTE689trial #perioperativeimmunotherapy #PDL1positiveHNSCC
zurl.co/y2cQh

Waterfall plot showing change in longest diameter of primary tumor. Y-axis labeled 'Change in longest diameter of primary tumor, %' ranges from -100 to 100. X-axis labeled 'Patients'. Plot shows progressive, stable, partial, and complete responses.

Intratumoral NBTXR3 followed by #Radiotherapy showed feasibility and promising response rates in cisplatin- or cetuximab-ineligible patients with locally advanced #HNSCC. ja.ma/4uFjVXr

#FGF9 #HNSCC #HeadandNeckSquamousCellCarcinima

High FGF9 HR=2.5⬇️HNSCC survival

7-gene NOTCH module score➡️
Survival
Immunosuppressive TME
Anti-PD-1 immunotherapy response (low NOTCH score 92%; high 8%)
Chemo sensitivity

#JStomatolOralMaxillofacSurg 2025
www.sciencedirect.com/science/arti...

Data from an exploratory expansion cohort of a phase 1b trial showed less-frequent dosing of ficerafusp alfa in combination with pembrolizumab produced deep and durable responses in patients with recurrent/metastatic #HNSCC #oncology

Read more: www.onclive.com/view/less-fr...

JAMA Otolaryngology-Head & Neck Surgery journal cover. Title: Individualized Prognostic Counseling for Decision-Making in Head and Neck Cancer. Authors: Maarten C. Dorr, Arta Hoesseini, Aniel Sewnaik. Published Online: January 2, 2026.

Individualized prognostic counseling using an online model was linked to reduced decisional conflict and regret and more active decision-making in #HNSCC patients.

ja.ma/4be5a6v

A phase 1 study of berzosertib (M6620, VX‐970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950) In a phase 1 trial, selective ATR inhibitor berzosertib with definitive radiation and cisplatin in locally advanced head and neck squamous cell cancers was well tolerated but did not improve complete....

A Phase 1 study by Dr. Aarti Bhatia combined berzosertib with cisplatin + RT in LA #HNSCC. The regimen was feasible + safe, but did not improve response rates compared w/historical chemoradiation—highlighting the need for better radiosensitizers.
acsjournals.onlinelibrary.wiley.com/doi/10.1002/...

Figure 2: Genomic Landscape and Longitudinal Minimal Residual Disease Dynamics. Chart A: Oncoplot showing gene variants like TTN, TP53, FAT1 and variant types. Chart B: Gene variants by stage, with bar graphs showing percentage of patients carrying variants.

In patients with locally advanced #HNSCC, ctDNA-based minimal residual disease positivity after treatment completion was associated with higher recurrence and worse survival, supporting its use as a prognostic biomarker. ja.ma/46YDqQL

The graphic shows four plots: An Alluvial plot about trial phase and reasons for failure, a graph of reasons for failure by treatment type, a graph of reason for failure by funder type, and a scatter plot showing principal components.

Strategic sponsor decisions and poor accrual are the leading reasons for early termination of #HNSCC clinical trials, especially in industry-funded and phase 1 studies. ja.ma/4urXGEf

JAMA Otolaryngology-Head & Neck Surgery journal excerpt. Headline: Neoadjuvant Immunotherapy and Chemoimmunotherapy Regimens in Head and Neck Cancer. Authors: Hannah Q. Baratz, et al. Published online: March 12, 2026. doi: text@1

Neoadjuvant chemoimmunotherapy for resectable locoregionally advanced head and neck squamous cell carcinoma (#HNSCC) was associated with higher rates of major and complete pathologic response compared with immunotherapy alone.

ja.ma/4smWxw9

#MHNCS26 phase II trial of the trop-2 / Topo 1 ADC, Sacituzumab Govitecan in recurrent post PD1 metastatic #HNSCC presented as a TIP #MedIQMHNCS26

#MHNCS26 encouraging results of NBTXR3 with SBRT in recurrent post PD1 failure R/M #HNSCC with ORR exceeding 60% in this early data #MedIQMHNCS26

#MHNCS 26 FORTIFI HN01 A pivotal phase III trial examining Ficerafusp Alfa + Pembro vs Pembro in HPV unrelated #HNSCC, TIP presentation #MedIQMHNCS26

#MHNCS26 AHEAD MERIT pivotal phase II / III trial of HPV 16 E6,E7 mRNA immunotherapy : BNT 113 + Pembro vs Pembro in RM PDL1 + HPV 16 #HNSCC, TIP #MedIQMHNCS26

#MHNCS26 updates from KN689 as to surgical data; EFS correlates with mPR; surgical rate is similar in both arms, #MedIQMHNCS26 #HNSCC

#MHNCS26 predictive and prognostic IO markers to be analyzed for R/M #HNSCC in the Phoenix tissue procurement study, so far 52 patients enrolled; a TIP poster session #MedIQMHNCS26

#MHNCS26 ongoing Evolve trial is a global study of Volrustamab vs observation post definitive Chemo RT in LA #HNSCC updated in a TIP poster session #MedIQMHNCS26

#MHNCS26 preoperative SC Amivantamab shows tolerability and encouraging responses with ORR of 46% in this cohort of pre and post Ami + Pembro resectable HPV - #HNSCC #MedIQMHNCS26

#MHNCS26 the only STAT3 targeted ASO shows no increase in response compared to single agent Pembro in 1st line randomized PEMDA Denvatirsen Pembro vs Pembro phase II study #MedIQMHNCS26 #HNSCC

#MHNCS26 encouraging responses with Ficerafusp Alfa 2000 mg Q 2 weeks and Pembro 400 Q 6 in 1st line RM HPV - HNSCC , ORR 48% CR 26% #MedIQMHNCS26 #HNSCC

Encouraging results with ORR 56% CR 10% shrinkage of tumor in 82% in Origami 4 Amivantamab + Pembro cohort #MHNCS26
#MedIQMHNCS26 #HNSCC

Forest plots show associations between treatment response and disease-free survival. Plot A: Partial pathologic response. Plot B: Major pathologic response. Studies include text@11, text@6, text@13, text@19, text@18, text@12, text@22, text@21, text@23.

Among adults with mucosal #HNSCC receiving neoadjuvant immune checkpoint inhibition, pooled analysis demonstrated that partial and major pathologic responses correlated with improved disease-free survival, but not overall survival.

bit.ly/4kiD8JH

AVEO Oncology Completes First Analysis of FIERCE-HN Study for Head and Neck Cancer Treatment AVEO Oncology announces the successful completion of the first interim analysis for the global FIERCE-HN study, focusing on a promising combination therapy for patients with advanced head and neck cancer.

AVEO Oncology Completes First Analysis of FIERCE-HN Study for Head and Neck Cancer Treatment #United_States #Boston #AVEO_Oncology #HNSCC #ficlatuzumab

🦙 Our new #review article is out now.💡
In "Ancient and Emerging Nanostructures for Innovations to Fight #HeadandNeckCancer" we highlight how diverse technologies are shaping the future for #HNSCC thearpy, also including our research focus about #Nanobodies🦙
Read more 👉 www.mdpi.com/2073-4409/15...

CDK7 targeting suppresses #HNSCC progression by downregulating genes involved in cell cycle progression & #DNARepair, highlighting CDK7 inhibition as a potent therapeutic strategy to overcome treatment resistance. @universidadoviedo.bsky.social

#OpenAccess: doi.org/10.1038/s413...

PD-1 Inhibition Plus Chemotherapy Offers Survival Benefits in Frontline HNSCC | OncLive Real-world data showed that adding PD-1 inhibitors to induction chemotherapy extended OS and PFS vs chemotherapy alone in frontline HNSCC.

PD-1 Inhibition Plus Chemotherapy Offers Survival Benefits in Frontline HNSCC #oncology #HNSCC
www.onclive.com/view/pd-1-in...

Illustration titled "Figure 1. Subsites of Head and Neck Squamous Cell Carcinomas" from JAMA, published online December 15, 2025, showing the anatomy of the upper aerodigestive tract and cancer presentation, detailing areas like the frontal sinus, nasal cavity, and tongue.

In 2024, approximately 58 450 individuals were diagnosed with oral cavity and pharynx cancer and 12 650 were diagnosed larynx cancer in the US.

This Review discusses head and neck squamous cell carcinomas (#HNSCC) of the upper aerodigestive tract.

bit.ly/4rHpLWf